Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Open-Label Study Of Recombinant Human Interleukin-12 (NSC 672423) In Mycosis Fungoides (MF) Patients With Cross-Over To Phase I Evaluation Of Escalating Doses Of Interleukin-2 (NSC 373364) Administered With Interleukin-12

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00052377
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:23.600604+00:00
Published At
2013-01-16T00:00:00+00:00
Record Updated At
2013-01-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2013-01-16"
protocolSection.identificationModule.nctId
"NCT00052377"
protocolSection.identificationModule.officialTitle
"A Phase II Open-Label Study Of Recombinant Human Interleukin-12 (NSC 672423) In Mycosis Fungoides (MF) Patients With Cross-Over To Phase I Evaluation Of Escalating Doses Of Interleukin-2 (NSC 373364) Administered With Interleukin-12"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Stage I Cutaneous T-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage I Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Stage II Cutaneous T-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage II Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Stage III Cutaneous T-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage III Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage IV Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.